Prof Michel Reijnen (Rijnstate Hospital, Arnhem, NL) discusses 4-year results from the In.Pact Global Study focusing on outcomes in CLI patients treated with drug-coated balloons (DCBs).
The rationale of In.Pact Global Study is to collect safety and efficacy data on the IN.PACT Admiral™ Drug Eluting Balloon (DEB) in treatment of atherosclerotic disease in the superficial femoral and/or popliteal arteries in a "real world" patient cohort.
Recorded remotely from Arnhem, 2021.
1. What is the burden of critical limb ischemia (CLI) and what unmet needs remain for these patients?
2. Why was this study initiated?
3. What was the design and cohort of the study?
4. What were your findings?
5. What are the "take-home" messages?
6. What are the next steps?
Editor: Mirjam Boros
Recording Editor: Natascha Wienand